NCT01906346

Brief Summary

Cocaine-use disorders continue to be a significant public health concern, yet no effective medications have been identified. The goal of this study is to establish a research platform for the development of medications for treatment of cocaine abuse and dependence. This study will incorporate self-administration procedures and a non-drug alternative reinforcer, which is hypothesized to reduce the reinforcing effects of cocaine.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
9

participants targeted

Target at below P25 for early_phase_1

Timeline
Completed

Started Jan 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 16, 2013

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 24, 2013

Completed
5 months until next milestone

Study Start

First participant enrolled

January 1, 2014

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
4 years until next milestone

Results Posted

Study results publicly available

May 17, 2019

Completed
Last Updated

May 17, 2019

Status Verified

April 1, 2019

Enrollment Period

1.4 years

First QC Date

July 16, 2013

Results QC Date

April 19, 2019

Last Update Submit

April 19, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative

    The reinforcing effects of cocaine were determined using a modified progressive ratio procedure in which subjects made 9 choices between each available cocaine dose and one of three money alternatives.

    9 choice trials per cocaine dose level with each trial separated by 30 minutes

Study Arms (3)

Low Value Alternative Reinforcer

EXPERIMENTAL

A low value reinforcer will be made available as an alternative to cocaine and placebo.

Drug: CocaineDrug: Placebo

Medium Value Reinforcer

EXPERIMENTAL

A medium value reinforcer will be made available as an alternative to cocaine and placebo.

Drug: CocaineDrug: Placebo

High Value Reinforcer

EXPERIMENTAL

A high value reinforcer will be made available as an alternative to cocaine and placebo.

Drug: CocaineDrug: Placebo

Interventions

Three active doses of cocaine will be made available for self-administration during experimental sessions.

High Value ReinforcerLow Value Alternative ReinforcerMedium Value Reinforcer

Placebo cocaine will be made available for self-administration during experimental sessions.

High Value ReinforcerLow Value Alternative ReinforcerMedium Value Reinforcer

Eligibility Criteria

Age21 Years - 45 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Cocaine dependence, otherwise healthy

You may not qualify if:

  • Laboratory results outside of clinically acceptable ranges, history of or current serious physical or psychiatric disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Laboratory of Human Behavioral Pharmacology

Lexington, Kentucky, 40536-0086, United States

Location

MeSH Terms

Conditions

Cocaine-Related Disorders

Interventions

Cocaine

Condition Hierarchy (Ancestors)

Substance-Related DisordersChemically-Induced DisordersMental Disorders

Intervention Hierarchy (Ancestors)

TropanesAzabicyclo CompoundsAza CompoundsOrganic ChemicalsAlkaloidsHeterocyclic CompoundsBridged Bicyclo Compounds, HeterocyclicHeterocyclic Compounds, Bridged-Ring

Results Point of Contact

Title
Joshua A. Lile, Ph.D.
Organization
University of Kentucky

Study Officials

  • Joshua A Lile, Ph.D

    University of Kentucky

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Joshua A. Lile, Ph.D., Associate Professor of Behavioral Science

Study Record Dates

First Submitted

July 16, 2013

First Posted

July 24, 2013

Study Start

January 1, 2014

Primary Completion

June 1, 2015

Study Completion

June 1, 2015

Last Updated

May 17, 2019

Results First Posted

May 17, 2019

Record last verified: 2019-04

Locations